icaritin + bevacizumab + FOLFIRI

This is a combination regimen consisting of icaritin, bevacizumab, and FOLFIRI. - **Icaritin** is a small molecule derived from the Epimedium genus (herbal source), under investigation for its antitumor and immunomodulatory properties. It acts as an immune modulator and may inhibit multiple signaling pathways involved in tumor growth. - **Bevacizumab** is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis (the formation of new blood vessels) required for tumor growth. - **FOLFIRI** is a standard chemotherapy regimen composed of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. Folinic acid enhances the effect of 5-FU; fluorouracil disrupts DNA synthesis as an antimetabolite; irinotecan inhibits topoisomerase I, preventing DNA replication[1][2][3][4][5]. This combination would be considered investigational, likely intended for advanced or metastatic solid tumors such as colorectal cancer or other gastrointestinal cancers where FOLFIRI plus targeted agents are commonly used[2][5]. The addition of icaritin suggests exploration in clinical trials.